Statera Biopharma is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Co.'s proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia. Co.'s product candidate in this field is entolimod, an immune-stimulatory agent, which Co. is developing as a radiation countermeasure and other indications in radiation oncology. We show 6 historical shares outstanding datapoints in our coverage of STAB's shares outstanding history.
Understanding the changing numbers of STAB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like STAB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching STAB by allowing them to research STAB shares outstanding history
as well as any other stock in our coverage universe. |
Free STAB Email Alerts:
Video: Shares Outstanding Importance
